Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests.
Animals
Antibodies, Monoclonal
/ immunology
Antigen-Antibody Reactions
COVID-19
/ pathology
Coronavirus Nucleocapsid Proteins
/ genetics
Epitopes
/ immunology
Humans
Immunization
Immunoassay
/ methods
Mice
Mice, Inbred BALB C
Phosphoproteins
/ genetics
Point-of-Care Systems
SARS-CoV-2
/ isolation & purification
Silver
/ chemistry
COVID-19
SARS-CoV-2
monoclonal antibody
nucleoprotein
point-of-care testing
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
15 06 2021
15 06 2021
Historique:
received:
25
10
2020
revised:
02
04
2021
accepted:
13
05
2021
pubmed:
25
5
2021
medline:
25
5
2021
entrez:
24
5
2021
Statut:
ppublish
Résumé
The ongoing coronavirus disease 2019 (COVID-19) pandemic is a major global public health concern. Although rapid point-of-care testing for detecting viral antigen is important for management of the outbreak, the current antigen tests are less sensitive than nucleic acid testing. In our current study, we produce monoclonal antibodies (mAbs) that exclusively react with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and exhibit no cross-reactivity with other human coronaviruses, including SARS-CoV. Molecular modeling suggests that the mAbs bind to epitopes present on the exterior surface of the nucleocapsid, making them suitable for detecting SARS-CoV-2 in clinical samples. We further select the optimal pair of anti-SARS-CoV-2 nucleocapsid protein (NP) mAbs using ELISA and then use this mAb pair to develop immunochromatographic assay augmented with silver amplification technology. Our mAbs recognize the variants of concern (501Y.V1-V3) that are currently in circulation. Because of their high performance, the mAbs of this study can serve as good candidates for developing antigen detection kits for COVID-19.
Identifiants
pubmed: 34027498
doi: 10.1016/j.xcrm.2021.100311
pii: S2666-3791(21)00154-3
pmc: PMC8126173
doi:
Substances chimiques
Antibodies, Monoclonal
0
Coronavirus Nucleocapsid Proteins
0
Epitopes
0
Phosphoproteins
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
Silver
3M4G523W1G
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100311Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Y. Yamaoka, S.K., K. Suzuki, and D.A. are current employees of Kanto Chemical Co., Inc.; J.K., A.W., and T.T. are current employees of FUJIFILM Corporation. A.R. received collaborative research grant from Kanto Chemical Co., Inc. and FUJIFILM Corporation. Provisional patent applications relevant to this study were filed. The remaining authors declare no competing interests.
Références
J Clin Virol. 2020 Aug;129:104446
pubmed: 32512376
Front Microbiol. 2016 Apr 20;7:509
pubmed: 27148198
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
Acta Pharm Sin B. 2020 Jul;10(7):1228-1238
pubmed: 32363136
Nat Methods. 2015 Jan;12(1):7-8
pubmed: 25549265
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Lancet Infect Dis. 2019 Aug;19(8):852-861
pubmed: 31155318
Biochem Biophys Res Commun. 2021 Jan 29;538:54-62
pubmed: 33039147
PLoS One. 2015 Feb 04;10(2):e0116715
pubmed: 25650570
Brief Bioinform. 2019 Jul 19;20(4):1160-1166
pubmed: 28968734
Front Microbiol. 2013 Nov 26;4:346
pubmed: 24324462
J Virol Methods. 2011 Dec;178(1-2):82-6
pubmed: 21911008
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32404480
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Clin Diagn Lab Immunol. 2005 Jul;12(7):848-54
pubmed: 16002634
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
Curr Opin Biotechnol. 2006 Aug;17(4):373-80
pubmed: 16828277
J Virol. 2020 Jun 16;94(13):
pubmed: 32546606
J Biol Chem. 1994 Oct 7;269(40):24523-6
pubmed: 7929118
Methods Mol Biol. 2014;1137:1-15
pubmed: 24573470
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Clin Microbiol. 2015 Apr;53(4):1178-82
pubmed: 25631809
Electrophoresis. 1997 Dec;18(15):2714-23
pubmed: 9504803
Front Microbiol. 2014 May 13;5:208
pubmed: 24860558
Cell Res. 2020 Dec;30(12):1143-1145
pubmed: 32901111
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307
pubmed: 32074516
J Biol Chem. 1996 Aug 30;271(35):21439-45
pubmed: 8702926
J Clin Lab Anal. 2005;19(4):150-9
pubmed: 16025480
Protein Sci. 2020 Sep;29(9):1890-1901
pubmed: 32654247
Lancet. 2020 Aug 8;396(10248):e17
pubmed: 32771112
Lancet. 2020 Sep 5;396(10252):e23
pubmed: 32866429
Euro Surveill. 2019 Feb;24(6):
pubmed: 30755292
Nat Methods. 2008 Dec;5(12):1011-7
pubmed: 19054851
PLoS One. 2009 Oct 08;4(10):e7388
pubmed: 19812689
J Immunol Methods. 2006 Apr 20;311(1-2):57-70
pubmed: 16516908
Sci Rep. 2015 Jun 10;5:11333
pubmed: 26061673
Mol Biomed. 2020;1(1):2
pubmed: 34765991
J Virol Methods. 2020 Jan;275:113736
pubmed: 31669454
J Med Virol. 2021 Apr;93(4):2132-2140
pubmed: 33090512
J Clin Virol. 2020 Aug;129:104455
pubmed: 32485618
J Clin Microbiol. 2005 Nov;43(11):5452-6
pubmed: 16272469
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32603652
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32839250
Clin Infect Dis. 2021 Apr 8;72(7):1291-1292
pubmed: 32445559
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Methods Mol Biol. 2010;607:23-30
pubmed: 20204845